Target intelligence / Profile preview

NADH:ubiquinone oxidoreductase subunit C1 (NDUFC1)

Target
NDUFC1
Molecular classification
Enzyme (Complex I subunit), Mitochondrial protein, Accessory/supernumerary subunit of enzyme complex
01

Overview

NADH:ubiquinone oxidoreductase subunit C1 (NDUFC1) is an accessory subunit of mitochondrial complex I, the first enzyme in the electron transport chain responsible for transferring electrons from NADH to ubiquinone, a critical step in oxidative phosphorylation and cellular ATP production. NDUFC1 is not directly involved in electron catalysis but is essential for the structural stability and assembly of the large multi-protein complex I, contributing to mitochondrial energy production and metabolism. Dysregulation of NDUFC1, particularly its overexpression, has been implicated in cancer (e.g., gastric cancer), where it appears to regulate cell proliferation, apoptosis, cell cycle, and migration through its influence on mitochondrial metabolism. It has also been associated with mitochondrial diseases and is found mutated or dysregulated in certain metabolic and neurodegenerative disorders. No current therapeutics are known to specifically target NDUFC1, but inhibitors of Complex I as a whole (e.g., rotenone, metformin) affect its function.

Other names
NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrialCI-KFYIKFYIComplex I-KFYINADH-ubiquinone oxidoreductase KFYI subunitcomplex I KFYI subunit
02

Mechanism of action

Inhibition of complex I (i.e., by rotenone or metformin) decreases NADH oxidation, impairs mitochondrial respiration and ATP synthesis, increases reactive oxygen species (ROS), and disrupts cellular energy status.

03

Biological functions

Mitochondrial electron transportOxidative phosphorylationRegulation of cellular energy metabolismAccessory structural role in NADH dehydrogenase (Complex I) assembly and stability
04

Disease associations

Mitochondrial diseaseCancer (notably gastric cancer)Potential other roles in metabolic disorders
05

Safety considerations

General inhibition of complex I (inclusive of NDUFC1) can lead to mitochondrial dysfunction, lactic acidosis, and neurodegeneration; not specific to NDUFC1 but relevant for complex I targeting drugs
06

Interacting drugs

No direct drugs known to specifically target NDUFC1; general complex I inhibitors include rotenone and metformin but they act on the entire complex, not the subunit specifically
07

Biomarkers

Overexpression in tumor tissue (e.g., biomarker for gastric cancer prognosis/diagnosis)Mitochondrial disease gene screening panels

Beyond the preview

Go deeper on NADH:ubiquinone oxidoreductase subunit C1 (NDUFC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit C1 (NDUFC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call